Patent application number | Description | Published |
20080233156 | Pharmaceutical compositions - Provided herein is a method of treating a condition in a host that is responsive to an agonist, the method comprising administering to the host a multi-layer pharmaceutical composition comprising the agonist and an antagonist thereof, wherein the agonist and antagonist are not in direct contact with one another in the intact form of the composition. | 09-25-2008 |
20100151014 | PHARMACEUTICAL COMPOSITION - Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated. | 06-17-2010 |
20100152221 | PHARMACEUTICAL COMPOSITION - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated. | 06-17-2010 |
20120121667 | Pharmaceutical Composition - Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated. | 05-17-2012 |
20130122065 | Pharmaceutical Composition - Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated. | 05-16-2013 |
20130337020 | Pharmaceutical Compositions - Provided herein is a method of treating a condition in a host that is responsive to an agonist, the method comprising administering to the host a multi-layer pharmaceutical composition comprising the agonist and an antagonist thereof, wherein the agonist and antagonist are not in direct contact with one another in the intact form of the composition. | 12-19-2013 |
20140037721 | Pharmaceutical Composition - Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated. | 02-06-2014 |
20140056975 | Pharmaceutical Composition - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated. | 02-27-2014 |
20150104519 | Pharmaceutical Compositions - Provided herein are formulations and methods for treating pain in human beings. Also provided are optimal ratios at which an opioid and an opioid antagonist may be combined for administration to humans such that the opioid activity is inhibited. These ratios may also be used to formulate compositions containing both an opioid and an opioid antagonist within a single pharmaceutical dosing unit. | 04-16-2015 |
20160058755 | Pharmaceutical Composition - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated. | 03-03-2016 |
Patent application number | Description | Published |
20090196890 | PHARMACEUTICAL COMPOSITIONS - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated. | 08-06-2009 |
20150297527 | Pharmaceutical Compositions - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated. | 10-22-2015 |
Patent application number | Description | Published |
20100310739 | Infused Roasted Seeds And Methods Of Making Thereof - Roasted infused seeds and a process for preparing roasted infused seeds are described. In one aspect, the roasted infused seeds may have salt, flavors, nutrients, colors, and/or functional ingredients as well as mixtures of these components infused internally into the seed. By infusing such components into the seeds, the methods described herein provide roasted seeds with unique flavors, nutrients, colors, textures, densities, and/or other functionalities. | 12-09-2010 |
20130177680 | INFUSED ROASTED SEEDS AND METHODS OF MAKING THEREOF - Roasted infused seeds and a process for preparing roasted infused seeds are described. In one aspect, the roasted infused seeds may have salt, flavors, nutrients, colors, and/or functional ingredients as well as mixtures of these components infused internally into the seed. By infusing such components into the seeds, the methods described herein provide roasted seeds with unique flavors, nutrients, colors, textures, densities, and/or other functionalities. | 07-11-2013 |
Patent application number | Description | Published |
20080253959 | Synthesis crystalline molecular sieves - In a process for synthesizing a crystalline molecular sieve, an aqueous synthesis mixture is produced capable of forming the crystalline molecular sieve. Crystallization of the synthesis mixture is induced so as to form crystals of said molecular sieve in the synthesis mixture and, when crystallization is complete, the molecular sieve crystals are allowed or caused to separate from the remainder of the synthesis mixture to produce a solid phase comprising said molecular sieve crystals and a supernatant liquid phase. The supernatant liquid phase is then decanted from the solid phase to recover the molecular sieve crystals and the crystals are dried without initially being subjected to washing or filtration. | 10-16-2008 |
20090112036 | Selective oligomerization of isobutene - A process for oligomerizing isobutene includes contacting a feedstock including isobutene with a catalyst comprising an EMM-10 molecular sieve under conditions effective to oligomerize said isobutene and produce an effluent containing less isobutene than the feedstock. | 04-30-2009 |
20130225890 | Liquid Phase Alkylation Process - The present invention provides a process for producing a monoalkylated aromatic compound comprising the step of contacting an alkylatable aromatic compound with an alkylating agent in the presence of a catalyst composition under effective alkylation conditions, said catalyst composition comprising MCM-56 and a binder, such that the crystal/binder weight ratio in the catalyst composition is from above 20/80 to about 80/20. | 08-29-2013 |
20130251627 | High Throughput Process for Manufacturing Molecular Sieves - A method of crystallizing a crystalline molecular sieve having a pore size in the range of from about 2 to about 19 Å, said method comprising the steps of (a) providing a mixture comprising at least one source of ions of tetravalent element (Y), at least one hydroxide source (OH | 09-26-2013 |
20130324760 | Hydrocarbon Conversion Process Using a High Throughpout Process for Manufacturing Molecular Sieves - A method of crystallizing a crystalline molecular sieve having a pore size in the range of from about 2 to about 19 Å, said method comprising the steps of (a) providing a mixture comprising at least one source of ions of tetravalent element (Y), at least one hydroxide source (OH | 12-05-2013 |
20140157986 | DDR TYPE ZEOLITES WITH STABILIZED ADSORPTION - Methods are provided for forming zeolite crystals suitable for gas phase separations with transport characteristics that are stable over time. The zeolitic materials and/or corresponding methods of synthesis or treatment described herein provide for improved stability in the early stages of process operation for some types of gas phase separations. The methods allow for synthesis of DDR type zeolites that have reduced contents of alkali metal impurities. The synthetic methods for reducing the non-framework alkali metal atom or cation impurity content appear to have little or no impact on the DDR crystal structure and morphology. | 06-12-2014 |
20140161717 | SYNTHESIS OF ZSM-58 CRYSTALS WITH IMPROVED MORPHOLOGY - Methods are provided for synthesizing ZSM-58 crystals with an improved morphology and/or an improved size distribution. By controlling the conditions during synthesis of the ZSM-58 crystals, crystals of a useful size with a narrow size distribution can be generated. Additionally, by controlling the ratio of water content to silica content in the synthesis mixture, it has unexpectedly been found that ZSM-58 crystals can be formed with an improved morphology. The improved morphology can result in ZSM-58 crystals with a more uniform size across the various dimensions of the crystal, which allows for more uniform diffusion within the crystal. This is in contrast to conventionally synthesized crystals, where the size of the crystal can vary along different axes of the crystals. | 06-12-2014 |
20140194653 | High Throughput Process for Manufacturing Molecular Sieves of MFI Framework Type - A process for converting hydrocarbons comprising the step of contacting said hydrocarbons under conversion conditions with a crystalline molecular sieve having a pore size in the range of from about 2 to about 19 Å, said molecular sieve made by a method comprising the steps of (a) providing a mixture comprising at least one source of ions of tetravalent element (Y), at least one trivalent element hydroxide source (OH | 07-10-2014 |
20140234207 | MCM-56 Manufacture - The present invention provides an improved method for manufacturing high quality porous crystalline MCM-56 material. It also relates to the MCM-56 material manufactured by the improved method, catalyst compositions comprising same and use thereof in a process for catalytic conversion of hydrocarbon compounds. One such conversion process involves production of monoalkylated aromatic compounds, particularly ethylbenzene and cumene, by the liquid or partial liquid phase alkylation of alkylatable aromatic compound, particularly benzene. | 08-21-2014 |
20140243567 | Liquid Phase Alkylation Process - The present invention provides a process for producing a monoalkylated benzene comprising the step of contacting benzene with an alkylating agent in the presence of a catalyst composition under effective alkylation conditions to form said monoalkylated benzene and polyalkylated benzene, said catalyst composition comprising MCM-56 and a binder, such that the crystal/binder weight ratio in said catalyst composition is from about 20/80 to about 80/20, wherein said polyalkylated benzene comprises dialkylated benzene and trialkylated benzene, and the weight ratio of trialkylated benzene to dialkylated benzene is in the range from about 0.08 to about 0.12. | 08-28-2014 |
20150182947 | SYNTHESIS OF ZSM-58 CRYSTALS WITH IMPROVED DIFFUSIVITY FOR USE IN GAS SEPARATIONS - Methods are provided for synthesizing ZSM-58 crystals with an improved morphology and/or an improved size distribution. By controlling the conditions during synthesis of the ZSM-58 crystals, crystals of a useful size with a narrow size distribution can be generated. Additionally, by controlling the ratio of water content to silica content in the synthesis mixture, it has unexpectedly been found that ZSM-58 crystals can be formed with an improved morphology. The improved morphology can result in ZSM-58 crystals with a more uniform size across the various dimensions of the crystal, which allows for more uniform diffusion within the crystal. This is in contrast to conventionally synthesized crystals, where the size of the crystal can vary along different axes of the crystals. | 07-02-2015 |
Patent application number | Description | Published |
20110286298 | ADJUSTABLE ORBIT IMBALANCE COMPENSATING ORBITAL SHAKER - An orbital shaker apparatus is provided, including a first shaft connected to a first bearing assembly at a first end and a mounting portion at the other. The first shaft is rotatable about a first shaft axis, and is connected to a motor. The second shaft has a bearing assembly on the mounting portion at one end and a platform at the other, and is aligned parallel to and offset from the first shaft by a distance. A counterweight rotor assembly is coupled to the mounting portion, and rotated by a belt driven by a pulley connected to the rotating shaft of a counterweight motor. The counterweight assembly includes two counterweight bearings, each having a counterweight wedge. The platform also includes supports for objects to be secured thereto. In use, as the counterweight rotor rotates, the second shaft, second bearing assembly, and platform describes a circular orbit with diameter 2R. | 11-24-2011 |
20120294107 | Adjustable Orbit Imbalance Compensating Orbital Shaker - An orbital shaker apparatus is provided, including a first shaft connected to a first bearing assembly at a first end and a mounting portion at the other. The first shaft is rotatable about a first shaft axis, and is connected to a motor. The second shaft has a bearing assembly on the mounting portion at one end and a platform at the other, and is aligned parallel to and offset from the first shaft by a distance. A counterweight rotor assembly is coupled to the mounting portion, and rotated by a belt driven by a pulley connected to the rotating shaft of a counterweight motor. The counterweight assembly includes two counterweight bearings, each having a counterweight wedge. The platform also includes supports for objects to be secured thereto. In use, as the counterweight rotor rotates, the second shaft, second bearing assembly, and platform describes a circular orbit with diameter 2R. | 11-22-2012 |
Patent application number | Description | Published |
20090136471 | TREATMENT OF PREMATURE BIRTH COMPLICATIONS - The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants. | 05-28-2009 |
20130259845 | TREATMENT OF PREMATURE BIRTH COMPLICATIONS - The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants. | 10-03-2013 |
Patent application number | Description | Published |
20090132288 | SYSTEM AND METHOD FOR FACILITATING CENTRALIZED CANDIDATE SELECTION AND MONITORING SUBJECT PARTICIPATION IN CLINICAL TRIAL STUDIES - A system and method of facilitating centralized and standardized remote ratings of subjects in clinical trial studies includes providing training to raters located at one or more central rating sites such that the raters are trained to apply substantially similar criteria in determining whether a candidate is a qualified subject for the clinical trial and/or in the actual assessment, or information collection, phase of the clinical trail. By having centralized, consistently trained raters that are independent of clinical trial investigators, inter-rater reliability is enhanced and potential bias is reduced, thus increasing the effectiveness of the clinical trial results by providing more qualified subjects and more accurate results. | 05-21-2009 |
20090198504 | RATER RESOURCE ALLOCATION SYSTEMS AND METHODS - Methods of allocating raters to assessment visits of studies, and tangible computer readable media including software that is adapted to control a computer to implement methods of allocating raters to assessment visits of studies, are provided. Raters are allocated by retrieving blinding information that includes at least one blinding criterion for a visit of a study, retrieving rater information for at least one rater associated with the study, comparing the retrieved rater information and the retrieved blinding information to identify one or more raters meeting the at least one blinding criterion and enabling selection of the identified one or more raters for allocation to the visit of the study. A rater may then be allocated to the visit by receiving a selection for at least one of the identified raters and allocating the at least one rater to the visit responsive to the received selection. | 08-06-2009 |
20100100397 | SYSTEM AND METHOD FOR FACILITATING CENTRALIZED CANDIDATE SELECTION AND MONITORING SUBJECT PARTICIPATION IN CLINICAL TRIAL STUDIES - A system and method of facilitating centralized and standardized remote ratings of subjects in clinical trial studies includes providing training to raters located at one or more central rating sites such that the raters are trained to apply substantially similar criteria in determining whether a candidate is a qualified subject for the clinical trial and/or in the actual assessment, or information collection, phase of the clinical trail. By having centralized, consistently trained raters that are independent of clinical trial investigators, inter-rater reliability is enhanced and potential bias is reduced, thus increasing the effectiveness of the clinical trial results by providing more qualified subjects and more accurate results. | 04-22-2010 |
20110071853 | SYSTEM AND METHOD FOR FACILITATING CENTRALIZED CANDIDATE SELECTION AND MONITORING SUBJECT PARTICIPATION IN CLINICAL TRIAL STUDIES - A system and method of facilitating centralized and standardized remote ratings of subjects in clinical trial studies includes providing training to raters located at one or more central rating sites such that the raters are trained to apply substantially similar criteria in determining whether a candidate is a qualified subject for the clinical trial and/or in the actual assessment, or information collection, phase of the clinical trail. By having centralized, consistently trained raters that are independent of clinical trial investigators, inter-rater reliability is enhanced and potential bias is reduced, thus increasing the effectiveness of the clinical trial results by providing more qualified subjects and more accurate results. | 03-24-2011 |
20110077962 | SYSTEM AND METHOD FOR FACILITATING CENTRALIZED CANDIDATE SELECTION AND MONITORING SUBJECT PARTICIPATION IN CLINICAL TRIAL STUDIES - A system and method of facilitating centralized and standardized remote ratings of subjects in clinical trial studies includes providing training to raters located at one or more central rating sites such that the raters are trained to apply substantially similar criteria in determining whether a candidate is a qualified subject for the clinical trial and/or in the actual assessment, or information collection, phase of the clinical trail. By having centralized, consistently trained raters that are independent of clinical trial investigators, inter-rater reliability is enhanced and potential bias is reduced, thus increasing the effectiveness of the clinical trial results by providing more qualified subjects and more accurate results. | 03-31-2011 |
20110282692 | SYSTEM AND METHOD FOR FACILITATING CENTRALIZED CANDIDATE SELECTION AND MONITORING SUBJECT PARTICIPATION IN CLINICAL TRIAL STUDIES - A system and method of facilitating centralized and standardized remote ratings of subjects in clinical trial studies includes providing training to raters located at one or more central rating sites such that the raters are trained to apply substantially similar criteria in determining whether a candidate is a qualified subject for the clinical trial and/or in the actual assessment, or information collection, phase of the clinical trail. By having centralized, consistently trained raters that are independent of clinical trial investigators, inter-rater reliability is enhanced and potential bias is reduced, thus increasing the effectiveness of the clinical trial results by providing more qualified subjects and more accurate results. | 11-17-2011 |
20120084093 | RATER RESOURCE ALLOCATION SYSTEMS AND METHODS - Methods of allocating raters to assessment visits of studies, and tangible computer readable media including software that is adapted to control a computer to implement methods of allocating raters to assessment visits of studies, are provided. Raters are allocated by retrieving blinding information that includes at least one blinding criterion for a visit of a study, retrieving rater information for at least one rater associated with the study, comparing the retrieved rater information and the retrieved blinding information to identify one or more raters meeting the at least one blinding criterion and enabling selection of the identified one or more raters for allocation to the visit of the study. A rater may then be allocated to the visit by receiving a selection for at least one of the identified raters and allocating the at least one rater to the visit responsive to the received selection. | 04-05-2012 |
Patent application number | Description | Published |
20120021303 | ELECTRICALLY RECHARGEABLE, METAL-AIR BATTERY SYSTEMS AND METHODS - The invention provides for a fully electrically rechargeable metal-air battery systems and methods of achieving such systems. A rechargeable metal air battery cell may comprise a metal electrode an air electrode, and an aqueous electrolyte separating the metal electrode and the air electrode. In some embodiments, the metal electrode may directly contact the electrolyte and no separator or porous membrane need be provided between the air electrode and the electrolyte. Rechargeable metal air battery cells may be electrically connected to one another through a centrode connection between a metal electrode of a first battery cell and an air electrode of a second battery cell. Air tunnels may be provided between individual metal air battery cells. In some embodiments, an electrolyte flow management system may be provided. | 01-26-2012 |
20120040254 | BIFUNCTIONAL (RECHARGEABLE) AIR ELECTRODES - Performance, properties and stability of bifunctional air electrodes may be improved by using modified current collectors, and improving water wettability of air electrode structures. This invention provides information on creating non-corroding, electrically rechargeable, bifunctional air electrodes. In some embodiments, this bifunctional air electrode includes a corrosion-resistant outer layer and an electrically conductive inner layer. In some embodiments, this bifunctional air electrode includes titanium suboxides formed by reducing titanium dioxide. Titanium suboxides may be corrosion-resistant and electrically conductive. | 02-16-2012 |
20130115531 | ELECTRICALLY RECHARGEABLE, METAL-AIR BATTERY SYSTEMS AND METHODS - The invention provides for a fully electrically rechargeable metal-air battery systems and methods of achieving such systems. A rechargeable metal air battery cell may comprise a metal electrode an air electrode, and an aqueous electrolyte separating the metal electrode and the air electrode. In some embodiments, the metal electrode may directly contact the electrolyte and no separator or porous membrane need be provided between the air electrode and the electrolyte. Rechargeable metal air battery cells may be electrically connected to one another through a centrode connection between a metal electrode of a first battery cell and an air electrode of a second battery cell. Air tunnels may be provided between individual metal air battery cells. In some embodiments, an electrolyte flow management system may be provided. | 05-09-2013 |
20130209919 | BIFUNCTIONAL (RECHARGEABLE) AIR ELECTRODES - Performance, properties and stability of bifunctional air electrodes may be improved by using modified current collectors, and improving water wettability of air electrode structures. This invention provides information on creating non-corroding, electrically rechargeable, bifunctional air electrodes. In some embodiments, this bifunctional air electrode includes a corrosion-resistant outer layer and an electrically conductive inner layer. In some embodiments, this bifunctional air electrode includes titanium suboxides formed by reducing titanium dioxide. Titanium suboxides may be corrosion-resistant and electrically conductive. | 08-15-2013 |
20150244031 | ELECTROCHEMICAL CELL WITH DIVALENT CATION ELECTROLYTE AND AT LEAST ONE INTERCALATION ELECTRODE - The present invention provides a novel electrochemical cell that comprises a cathode, an anode, and an electrolyte, where an ion species present in the electrolyte intercalates into the cathode upon discharge of the electrochemical cell. | 08-27-2015 |
Patent application number | Description | Published |
20140273958 | METHOD OF PROVIDING USER EQUIPMENT WITH ACCESS TO A NETWORK AND A NETWORK CONFIGURED TO PROVIDE ACCESS TO THE USER EQUIPMENT - The method of operating a network includes receiving, by an authentication, authorization and accounting (AAA) proxy of the network, authentication information for user equipment from a first wireless access point, the AAA proxy being a proxy for an authentication, authorization and accounting (AAA) server in a radiocommunication network, transmitting, by the AAA proxy, at least the received authentication information to the radiocommunication network, receiving, by the AAA proxy, first key information from the radiocommunication network, generating, by the AAA proxy, second key information based on the first key information and third key information based on the second key information, storing, by the AAA proxy, the first and second key information, and transmitting, by the AAA proxy, the third key information to the first wireless access point, the third key information allowing the user equipment access to a network via the first wireless access point. | 09-18-2014 |
Patent application number | Description | Published |
20140274587 | PUNCHING BAG AND SUSPENSION SYSTEM - A punching bag and suspension system is a boxing training device that is orientated horizontally, which permits the punching bag to move vertically, horizontally, diagonally, as well as a 360 degree range of motion. The punching bag has a plastic or metal cylindrical tube running through its core. The tube contains an opening on both sides extending to the outer circumference of the punching bag. These openings allow the tube, and therefore the punching bag, to slide along suspension member. At the center of the suspension member there is a weight that through gravitational pull, creates an orientation and return point for the punching bag. | 09-18-2014 |
20150352424 | PUNCHING BAG AND SUSPENSION SYSTEM - A punching bag and suspension system is a boxing training device that is orientated horizontally, which permits the punching bag to move vertically, horizontally, diagonally, as well as a 360 degree range of motion. The punching bag has a plastic or metal cylindrical tube running through its core. The tube contains an opening on both sides extending to the outer circumference of the punching bag. These openings allow the tube, and therefore the punching bag, to slide along suspension member. At the center of the suspension member there is a weight that through gravitational pull, creates an orientation and return point for the punching bag. | 12-10-2015 |
Patent application number | Description | Published |
20080293058 | Association of GSTM1 with autism and assays and methods based thereon - The present invention provides novel markers and assays for autism based on the association of GSTM1 with autism. The invention relates to the use and application of as a susceptibility marker for autism. GSTM1 may be combined with other markers in methods and assays for diagnosis, prenatal diagnosis, and assessment of autism. The invention further relates to a likelihood ratio test. In addition, the present invention discloses a novel method for identifying individuals who are genetically susceptible to have offspring with autism wherein the genotype of GSTM1, alone or in combination with other genetic markers, is determined. | 11-27-2008 |
20100143318 | GSTP1 AS TERATOGENIC ALLELE FOR AUTISM AND ASSAYS AND METHODS BASED THEREON - The present invention provides novel markers and assays for autism based on the association of GSTP1 with prevalence for having a child or children with autism or autistic disease. The invention relates to the use and application of GSTP1 as a susceptibility marker and teratogenic allele for autism. In particular the genotype of GSTP1 at amino acids 105 and 114, corresponding to nucleotides 313 and 341 are determined. GSTP1 may be combined with other markers in methods and assays for monitoring, managing, diagnosis, prenatal diagnosis, and assessment of autism. In addition, the present invention discloses a novel method for identifying individuals who are genetically susceptible to have offspring with autism wherein the genotype of GSTP1, alone or in combination with other genetic markers or other indicators of oxidative stress, is determined. | 06-10-2010 |
20110229883 | Biochemical Markers for Disease States and Genes for Identification of Biochemical Defects - The present invention relates to a system utilizing biochemical markers and genetic markers to diagnose, predict, and/or monitor intervention of a number of diseases and conditions that have unresolved oxidative stress as an important component. The present invention relates generally to markers and assays for diagnosing, predicting, and monitoring disease, particularly disease-relevant oxidative stress and lipid metabolites and mediators. The oxidative stress, lipid metabolite and lipid mediator biochemical and genetic markers may be further combined with other disease associated or disease relevant markers in methods and assays for diagnosis, monitoring, and assessment of disease, particularly of complex diseases with multi-component factors. The system, methods and assays are applicable to various diseases, including autism, asthma, and Alzheimer's disease. | 09-22-2011 |